Free shipping on all orders over $ 500

Torkinib (PP242)

Cat. No. M1981
Torkinib (PP242) Structure


Size Price Availability Quantity
Free Sample (0.5-1 mg)  USD 0 In stock
5mg USD 50  USD50 In stock
10mg USD 80  USD80 In stock
25mg USD 160  USD160 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Torkinib (PP242) is a first selective inhibitor that targets ATP domain of mTOR. PP242 displays selectivity for mTOR over other PI 3K family kinases (IC50 values are 0.102, 0.408, 1.27, 1.96 and 2.2 μM for p110γ, DNA-PK, p110δ, p110α and p110β respectively). PP242 induced ERK activation in MM cell lines as well as primary cells. PP242 could also inhibit phosphorylation of AKT on serine 473, a TORC2 substrate, while rapamycin was ineffective. PP242 was more effective than rapamycin in achieving cytoreduction and apoptosis in MM cells. In addition, PP242 was an effective agent against primary MM cells in vitro and growth of 8226 cells in mice. PP242 inhibits both S6K and 4EBP1 phosphorylation; activity causes a decrease in cap-dependent protein translation.

Customer Product Validations & Biological Datas
Source Oncotarget (2015). Figure 1. PP242
Method MTT test
Cell Lines Eras cells
Concentrations 1500 nM
Incubation Time 24 h
Results So, after 24 h treatment with pp242, MTT test reveals a sharp drop in cell viability (up to 90%) that is characteristic for dying cells.
Protocol (for reference only)
Cell Experiment
Cell lines PC-3, SKOV3, 786-O, and U87 cells
Preparation method In vitro proliferation and drug combination experiments.
Cells were seeded in triplicate wells of 96-well flat bottom culture plates for 48 hr in the presence of increasing concentrations of indicated inhibitors. Cell viability and median-effect dose affecting growth (GIC50) was determined using the MTS assay (Cell Titer 96 Aqueous One solution cell proliferation assay kit; Promega). Absorbance values (490 nm) were normalized to controls and expressed as %MTS conversion. Wells lacking cells but with MTS added were used as the zero value when normalizing. For drug combination experiments, a range of fixed ratios of inhibitors was used to assess synergy using the combination index (CI) with CalcuSyn software (Biosoft) according to the median-effect method as previously described 2. For proliferation experiments with PC-3, SKOV3, 786-O, and U87 cells, the CellTiter-Glo Luminesecent reagent (Promega) was used following the manufacturer’s instructions. Quantitation was performed as mentioned above.
Concentrations 0~10 μM
Incubation time 48 h
Animal Experiment
Animal models xenograft experiments with human Ph+ leukemia
Formulation PEG400 or 5% NMP, 15% PVP, 80% water
Dosages 60mg/kg once daily
Administration oral
Chemical Information
Molecular Weight 308.34
Formula C16H16N6O
CAS Number 1092351-67-1
Solubility (25°C) DMSO 50 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.


[1] Hoang B, et al. J Biol Chem. The PP242 mammalian target of rapamycin (mTOR) inhibitor activates extracellular signal-regulated kinase (ERK) in multiple myeloma cells via a target of rapamycin complex 1 (TORC1)/eukaryotic translation initiation factor 4E (eIF-4E)/RAF pathway and activation is a mechanism of resistance.

[2] Hoang B, et al. Blood. Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor.

[3] Janes MR, et al. Nat Med. Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor.

Related mTOR Products

Zederone, a germacrane-type sesquiterpene, has potently cytotoxic against human white blood cancer cells and human prostate cancer cells. Zederone significantly inhibits the proliferation and downregulates the protein expressions of mTOR, and phosphorylated p70 S6 kinase (p-p70s6K) in SKOV3 cells.


MHY-1685, a novel mammalian target of rapamycin (mTOR) inhibitor, provides opportunities to improve hCSC-based myocardial regeneration.


RMC-6272 (RM-006) is a bi-steric mTORC1-selective inhibitor. RMC-6272 exhibits potent and selective (> 10-fold) inhibition of mTORC1 over mTORC2. RMC-6272 shows improved inhibition of mTORC1 in comparison to Rapamycin, and induces more cell death in TSC2 null tumors.


eCF309 is a potent and highly selective mTOR inhibitor with remarkably low off-target activities (IC50 = 10-15 nM, both in vitro and in cells).


PQR626, a rapamycin derivative, is a potent, selective, orally active, and brain-penetrant mTOR inhibitor, with an IC50 and Ki of 5 nM and 3.6 nM, respectively. PQR626 can be can be used for the research of neurological disorders.

Abmole Inhibitor Catalog

Keywords: Torkinib (PP242), Torkinib supplier, mTOR, inhibitors, activators

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.